Triple-targeted therapy of dabrafenib, trametinib, and osimertinib for the treatment of the acquired BRAF V600E mutation after progression on EGFR-tyrosine kinase inhibitors in advanced EGFR -mutated non-small cell lung cancer patients.

MLA

Weng, Cheng-Di, et al. “Triple-Targeted Therapy of Dabrafenib, Trametinib, and Osimertinib for the Treatment of the Acquired BRAF V600E Mutation after Progression on EGFR-Tyrosine Kinase Inhibitors in Advanced EGFR -Mutated Non-Small Cell Lung Cancer Patients.” Translational Lung Cancer Research, vol. 13, no. 10, Oct. 2024, pp. 2538–48. EBSCOhost, https://doi.org/10.21037/tlcr-24-358.

APA

Weng, C.-D., Liu, K.-J., Jin, S., Su, J.-W., Yao, Y.-H., Zhou, C.-Z., Li, Y.-F., Chen, Z.-X., Chen, H.-J., Li, Y.-Y., Tang, K.-J., & Yang, J.-J. (2024). Triple-targeted therapy of dabrafenib, trametinib, and osimertinib for the treatment of the acquired BRAF V600E mutation after progression on EGFR-tyrosine kinase inhibitors in advanced EGFR -mutated non-small cell lung cancer patients. Translational Lung Cancer Research, 13(10), 2538–2548. https://doi.org/10.21037/tlcr-24-358

Chicago

Weng, Cheng-Di, Ke-Jun Liu, Shi Jin, Jun-Wei Su, Yi-Hui Yao, Cheng-Zhi Zhou, Yu-Fa Li, et al. 2024. “Triple-Targeted Therapy of Dabrafenib, Trametinib, and Osimertinib for the Treatment of the Acquired BRAF V600E Mutation after Progression on EGFR-Tyrosine Kinase Inhibitors in Advanced EGFR -Mutated Non-Small Cell Lung Cancer Patients.” Translational Lung Cancer Research 13 (10): 2538–48. doi:10.21037/tlcr-24-358.